Our Transactions
Leadership across the largest and most complex situations
Lead Financial Advisor
on its pending €8.0 billion
acquisition of
from Vodafone Group
2024
Exclusive Financial Advisor
on its pending ~$2.3 billion
acquisition of
2024
Independent Financial Advisor
on its pending acquisition of three fill-finish sites for an upfront payment of $11 billion from Novo Holdings following its $16.5 billion acquisition of Catalent
2024
Exclusive Financial Advisor
on its pending ~$35 billion
acquisition of
2024
Exclusive Financial Advisor
on its pending ~$12.6 billion
sale to
2024
Lead Financial Advisor
on its pending $11.5 billion
all-stock merger with
2024
Lead Financial Advisor
on its pending ~$13.4 billion
sale to
2023
Financial Advisor
on its pending ~$14.9 billion
sale to
2023
Financial Advisor
on its pending $60 billion
all-stock acquisition of
2023
Financial Advisor
on its up to $5.8 billion
acquisition of
2023
Financial Advisor
on its pending ~$20 billion
merger with
2023
Lead Left Bookrunner
$300 million
Follow-on Offering
2023
Exclusive Financial Advisor
on its chapter 11 restructuring of ~$1.9 billion of debt and $125 million DIP ABL financing
2023
Active Bookrunner
$1.1 billion IPO & $1.6 billion
Follow-on Offering
2023
Exclusive Financial Advisor
on its pre-packaged chapter 11 restructuring of ~$3.6 billion of debt and preferred equity
2023
Lead Financial Advisor
on its ~$36 billion
spin-off of
2021
Anouncement Date1
Status
Transaction
Value (M)
February 5, 2024
Closed
Advised the Ad Hoc Group of First Lien Term Loan Lenders and Secured Noteholders on GoTo Group’s Exchange Offer
$3,100
February 2, 2024
Closed
Acted as an Active Bookrunner on Vaxcyte’s Follow-on Offering
$863
February 1, 2024
Closed
Acted as an Active Bookrunner on Fractyl Health's initial public offering
$110
January 31, 2024
Closed
Acted as a Joint Bookrunner on Amer Sports’ Initial Public Offering
$1,570
January 30, 2024
Pending
Advising Amphenol on its acquisition of the Carlisle Interconnect Technologies business of Carlisle
$2,025
January 30, 2024
Closed
Acted as an Active Bookrunner on Astria Therapeutics' Underwritten Equity Offering
$125
January 29, 2024
Closed
Acted as an Active Bookrunner on Vera Therapeutics' Follow-on Offering
$288
January 25, 2024
Closed
Acted as Exclusive Global Placement Agent for the fundraise of Arlington Capital Partners Fund VI
$3,810
January 22, 2024
Pending
Advising Hg Capital on its minority stake sale in Argus Media to General Atlantic
N/A
January 22, 2024
Closed
Acted as a Placement Agent on Dianthus Therapeutics’ Private Placement Financing
$230
1Announcement date for M&A transactions represents the date publicly announced; announcement date for restructurings represents the date publicly announced or filed; announcement date for capital markets transactions represents the pricing date.